

## TITLE PAGE

**Type of manuscript:** Original Article

**Title:** Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012-2014)

**Authors:** Sonia VÁZQUEZ-MORÓN<sup>1\*</sup>, Juan BERENGUER<sup>2,3</sup>, Juan GONZÁLEZ-GARCÍA<sup>4</sup>, M<sup>a</sup> Ángeles JIMÉNEZ-SOUSA<sup>1</sup>, Isabel CANOREA<sup>1</sup>, Josep M GUARDIOLA<sup>5</sup>, Manuel CRESPO<sup>6</sup>, Carmen QUEREDA<sup>7</sup>, José SANZ<sup>8</sup>, Ana CARRERO<sup>2,3</sup>, Victor HONTAÑÓN<sup>4</sup>, Ana AVELLÓN<sup>1</sup>, Salvador RESINO<sup>1\*</sup>

**Authors' affiliations:**

(1) Laboratorio de Referencia e Investigación en Hepatitis Víricas, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.

(2) Unidad de Enfermedades Infecciosas/VIH; Hospital General Universitario "Gregorio Marañón", Madrid, Spain.

(3) Instituto de Investigación Sanitaria del Gregorio Marañón, Madrid, Spain.

(4) Unidad de VIH; Servicio de Medicina Interna, Hospital Universitario "La Paz"/IdiPAZ, Madrid, Spain.

(5) Hospital Santa Creu i Sant Pau, Barcelona, Spain

(6) Complejo Hospitalario Universitario; Fundación IIS Galicia Sur, Vigo; Pontevedra, Spain

(7) Hospital Universitario Ramón y Cajal. Madrid, Spain

(8) Hospital Universitario Príncipe de Asturias. Alcalá de Henares, Madrid, Spain

**Corresponding author:**

\*Salvador Resino; Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda); Carretera Majadahonda- Pozuelo, Km 2.2; 28220 Majadahonda (Madrid); Phone: +34918223266. E-mail: [sresino@isciii.es](mailto:sresino@isciii.es)

\*Sonia Vázquez Morón; Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda); Carretera Majadahonda- Pozuelo, Km 2.2; 28220 Majadahonda (Madrid); Phone: +34918223861. E-mail: [svazquez@isciii.es](mailto:svazquez@isciii.es)

**Supplemental Table 1.** Summary of immunoblot assay for IgM and IgG and clinical outcomes against hepatitis E virus in HIV/HCV-coinfected patients according to CD4+ T-cell status.

	<b>Healthy controls</b>	<b>CD4+ T-cells <math>\geq 350</math> cells/mm<sup>3</sup></b>	<b>CD4+ T-cells <math>&lt; 350</math> cells/mm<sup>3</sup></b>	<b><i>p</i>-value (a)</b>	<b><i>p</i>-value (b)</b>	<b><i>p</i>-value (c)</b>
<b>No.</b>	30	158	38			
<b>IgM against HEV</b>	0 (0%)	8 (5.1%)	2 (5.3%)	0.483	0.617	0.999
<b>IgG against HEV</b>	2 (6.7%)	26 (16.5%)	12 (31.6%)	0.265	<b>0.012</b>	<b>0.034</b>
<b>Acute hepatitis E</b>	0 (0%)	8 (5.1%)	2 (5.3%)	0.483	0.617	0.999
<b>Resolved hepatitis E</b>	2 (6.7%)	23 (14.6%)	11 (28.9%)	0.389	<b>0.020</b>	<b>0.035</b>
<b>Exposure to HEV</b>	2 (6.7%)	31 (19.6%)	13 (34.2%)	0.087	<b>0.006</b>	0.053

**Statistics:** Values expressed as number of cases (%). *P*-values were calculated by chi-squared test or Fisher's exact test as required. *P*-values: (a), healthy controls vs. HIV/HCV-coinfected with CD4+ T-cells  $\geq 350$  cells/mm<sup>3</sup>; (b), healthy controls vs. HIV/HCV-coinfected with CD4+ T-cells  $< 350$  cells/mm<sup>3</sup>; (c), HIV/HCV-coinfected with CD4+ T-cells  $< 350$  cells/mm<sup>3</sup> vs. HIV/HCV-coinfected with CD4+ T-cells  $\geq 350$  cells/mm<sup>3</sup>.

**Abbreviations:** HEV, Hepatitis E virus, HCV, Hepatitis C virus; HIV-1, Human immunodeficiency virus type 1.